Original Article
Effect analysis of atomization of recombinant human interferon α-2b on children with infantile hand-foot-mouth disease
Gao Nan, Yue Jin, Li Shujuan, Hu Rong, Zhang Ling
Published 2021-06-25
Cite as China Clin Pract Med, 2021, 12(3): 52-56. DOI: 10.3760/cma.j.cn115570-20210303.00560
Abstract
ObjectiveTo investigate the effect of atomization of recombinant human interferon α-2b in the treatment of hand, foot and mouth disease(HFMD)in children.
MethodsA total of 113 children with HFMD admitted to Zhengzhou University from July 2018 to October 2020 were selected, including 65 males and 48 females, aged(2.31±0.85)years old, ranging from 1 to 5 years old.They were randomly divided into recombinant human interferon α-2b group( n=57) and ribavirin group(n=56) by lotting.The recombinant human interferon α-2b group was treated with inhalation of recombinant human interferon α-2b, and the ribavirin group was treated with ribavirin spray.The improvement level of symptoms and signs, neurological function indexes, alanine aminotransferase(ALT), aspartate aminotransferase(AST), white blood cell count(WBC), phosphocatine kinase isoenzyme(CK-MB)levels were compared between the two groups.
ResultsThe subsidence time of oral ulcer[(2.81±0.63)d], antipyretic time[(2.61±0.52)d], improvement time of anorexia[(2.32±0.56)d]and scab formation time of hand and foot rash[(2.78±0.64)d]in recombinant human interferon α-2b group were all earlier than those in ribavirin group[(3.22±0.72)d, (3.37±0.70)d, (2.89±0.71)d, (3.17±0.59)d], and the difference was statistically significan(P<0.05). The disappearance time of nervous system symptoms such as drowsiness, nervousness, lethargy, limb shaking in the recombinant human interferon α-2b group[(2.21±1.13)d, (2.34±1.19)d, (2.31±0.82)d, (2.26±0.90)d]was earlier than that in the ribavirin group[(2.64±1.34)d, (3.18±1.25)d, (2.87±0.96)d, (3.06±1.12)d], and the difference was statistically significant(P<0.05). After treatment, the level of NSE in recombinant human interferon α-2b group[(13.14±1.67)mg/L]was lower than that in ribavirin group[(21.98±2.24)mg/L], and the difference was statistically significant(P<0.05). After treatment, the levels of ALT, AST, WBC and CK-MB in recombinant human interferon α-2b group[(33.79±4.86)U/L, (42.19±3.86)U/L, (7.19±0.76)×109/L, (24.38±2.86)U/L]were lower than those in ribavirin group[(37.65±5.37)U/L, (47.07±4.76)U/L, (8.13±0.86)×109/L, (29.68±3.14)U/L], and the difference was statistically significant(P<0.05).
ConclusionRecombinant human interferon α-2b can improve the immune function, myocardial function and liver function by inhibiting the proliferation of viral cells.It can improve nerve function by enhancing blood and oxygen supply to the central nervous system.
Key words:
Recombinant human interferon α-2b; Hand-foot-mouth disease; Neuron-specific enolase; Phosphocreatine kinase isoenzyme; Virus intection
Contributor Information
Gao Nan
Department of Infection Prevention and Control, Children′s Hospital Affiliated to Zhengzhou University, Zhengzhou 450000, China
Yue Jin
Department of Infectious Diseases, Children′s Hospital Affiliated to Zhengzhou University, Zhengzhou 450000, China
Li Shujuan
Department of Out-patient, Children′s Hospital Affiliated to Zhengzhou University, Zhengzhou 450000, China
Hu Rong
Department of Ultrasound Medicine, Children′s Hospital Affiliated to Zhengzhou University, Zhengzhou 450000, China
Zhang Ling
Department of Infection Prevention and Control, Children′s Hospital Affiliated to Zhengzhou University, Zhengzhou 450000, China
